Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedAug 28, 2025
DataAggregated Company Financials
Companies292
  • 7D0.6%
  • 3M5.2%
  • 1Y-12.6%
  • YTD-0.6%

The Pharma is pretty flat in the last 7 days, but Eli Lilly has stood out, gaining 3.4%. Unfortunately though, the industry is down 13% over the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 28 Aug 2025US$1.8tUS$387.8bUS$61.0b19.9x29x4.6x
Sat, 26 Jul 2025US$1.8tUS$384.0bUS$62.1b18.2x29.2x4.7x
Mon, 23 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x27.9x4.5x
Wed, 21 May 2025US$1.7tUS$382.6bUS$61.2b17.6x27.5x4.4x
Fri, 18 Apr 2025US$1.6tUS$380.5bUS$48.4b16.1x33.8x4.3x
Sun, 16 Mar 2025US$1.8tUS$380.5bUS$35.2b16.1x52.6x4.9x
Tue, 11 Feb 2025US$1.9tUS$380.7bUS$39.1b18.3x47.9x4.9x
Thu, 09 Jan 2025US$1.8tUS$369.3bUS$31.3b17.8x57.5x4.9x
Sat, 07 Dec 2024US$1.9tUS$373.8bUS$30.6b19.3x61.2x5x
Mon, 04 Nov 2024US$1.9tUS$373.2bUS$29.3b19.6x64.9x5.1x
Wed, 02 Oct 2024US$2.0tUS$364.1bUS$25.2b19.4x79.1x5.5x
Fri, 30 Aug 2024US$2.1tUS$363.3bUS$19.2b18x107x5.6x
Sun, 28 Jul 2024US$1.9tUS$357.5bUS$12.8b16.3x152.1x5.4x
Tue, 25 Jun 2024US$2.0tUS$358.2bUS$14.1b16.3x139x5.5x
Thu, 23 May 2024US$1.9tUS$358.3bUS$14.1b18.2x134.8x5.3x
Sat, 20 Apr 2024US$1.8tUS$357.7bUS$29.8b20.3x60.2x5x
Mon, 18 Mar 2024US$1.9tUS$355.4bUS$22.5b19.8x82.7x5.2x
Wed, 14 Feb 2024US$1.8tUS$354.9bUS$22.8b31x80.9x5.2x
Fri, 12 Jan 2024US$1.8tUS$375.2bUS$33.9b26.6x52.4x4.7x
Sun, 10 Dec 2023US$1.7tUS$375.1bUS$33.9b26.6x48.9x4.4x
Tue, 07 Nov 2023US$1.6tUS$376.9bUS$33.9b18.9x48.1x4.3x
Thu, 05 Oct 2023US$1.6tUS$381.8bUS$43.8b18.5x37.6x4.3x
Sat, 02 Sep 2023US$1.7tUS$381.4bUS$43.7b19.6x39.7x4.5x
Mon, 31 Jul 2023US$1.7tUS$393.6bUS$61.5b18.5x28x4.4x
Wed, 28 Jun 2023US$1.7tUS$392.8bUS$60.1b18.9x29x4.4x
Fri, 26 May 2023US$1.7tUS$392.9bUS$60.5b18.3x28.1x4.3x
Sun, 23 Apr 2023US$1.7tUS$402.6bUS$63.3b17.8x26.3x4.1x
Tue, 21 Mar 2023US$1.6tUS$401.1bUS$69.3b15.6x22.5x3.9x
Thu, 16 Feb 2023US$1.6tUS$401.8bUS$68.4b18.6x24.1x4.1x
Sat, 14 Jan 2023US$1.7tUS$403.7bUS$70.6b17.6x24.6x4.3x
Mon, 12 Dec 2022US$1.8tUS$403.7bUS$70.7b16.5x24.8x4.3x
Wed, 09 Nov 2022US$1.7tUS$403.8bUS$71.4b14.9x23.6x4.2x
Fri, 07 Oct 2022US$1.6tUS$403.0bUS$71.3b12.4x22x3.9x
Sun, 04 Sep 2022US$1.6tUS$403.0bUS$71.3b14.6x21.8x3.9x
Price to Earnings Ratio

21.8x


Total Market Cap: US$1.6tTotal Earnings: US$71.3bTotal Revenue: US$403.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.2x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 29.0x which is lower than its 3-year average PE of 52.2x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 5.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.88%
Healthcare0.058%
Pharma0.62%
Pharma0.62%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$734.173.4%
+US$21.9b		-21.9%PE47.8x
RGC Regencell Bioscience HoldingsUS$14.2415.5%
+US$944.5m		6,655.6%PB1048.6x
ELAN Elanco Animal HealthUS$18.495.9%
+US$511.7m		21.4%PE21.2x
TEVA Teva Pharmaceutical IndustriesUS$18.052.5%
+US$504.7m		-2.7%PS1.2x
TLRY Tilray BrandsUS$1.3729.2%
+US$340.5m		-19.4%PS1.8x

Latest News

MRK
US$84.07
Merck
7D
-2.3%
1Y
-28.4%
LLY
US$734.17
Eli Lilly
7D
3.4%
1Y
-21.9%
VTRS
US$10.42
Viatris
7D
-2.2%
1Y
-12.4%

Aging Populations And Asia Markets Will Unlock Future Value

The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
TLRY
US$1.37
Tilray Brands
7D
29.2%
1Y
-19.4%
ELAN
US$18.49
Elanco Animal Health
7D
5.9%
1Y
21.4%

Elanco Animal Health's (NYSE:ELAN) Profits Appear To Have Quality Issues

Aug 20
Elanco Animal Health's (NYSE:ELAN) Profits Appear To Have Quality Issues
PFE
US$25.07
Pfizer
7D
-2.6%
1Y
-12.7%
BMY
US$47.63
Bristol-Myers Squibb
7D
-1.3%
1Y
-2.9%
JNJ
US$176.79
Johnson & Johnson
7D
-1.2%
1Y
7.6%
PHAT
US$12.44
Phathom Pharmaceuticals
7D
17.0%
1Y
-23.3%
BHC
US$7.27
Bausch Health Companies
7D
-4.1%
1Y
23.2%

Improved Revenues Required Before Bausch Health Companies Inc. (NYSE:BHC) Stock's 30% Jump Looks Justified

Aug 16
Improved Revenues Required Before Bausch Health Companies Inc. (NYSE:BHC) Stock's 30% Jump Looks Justified
RPRX
US$36.06
Royalty Pharma
7D
-2.2%
1Y
25.2%
JAZZ
US$124.43
Jazz Pharmaceuticals
7D
3.2%
1Y
7.6%

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
TEVA
US$18.05
Teva Pharmaceutical Industries
7D
2.5%
1Y
-2.7%
ZTS
US$155.37
Zoetis
7D
-0.2%
1Y
-15.0%
AXSM
US$121.86
Axsome Therapeutics
7D
4.0%
1Y
36.8%
RGC
US$14.24
Regencell Bioscience Holdings
7D
15.5%
1Y
6,655.6%